Accumulating evidence indicates that METTL14 exerts multi-level immune regulatory effects in the TME by modulating T cells, regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and natural killer (NK) cells, thereby reshaping the immune landscape and regulating antitumor immunity. The gene discussed is METTL14; the disease is neoplasm.